Disease · MONDO_0011918

anxiety

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anxiety. Diseases, record MONDO_0011918. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011918

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anxiety; Open Targets
Open Targets ID: MONDO_0011918; Open Targets
Other names: Anxiousness, Excessive, persistent worry and fear, anxiety-related personality traits; Open Targets
MeSH: D001007; MeSH
Highest stage of its drugs: Approval, for 36 of its 155 drugs, from ATC; Open Targets

Drugs155

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALPRAZOLAM	CHEMBL661	Small molecule	Approval	ATC	7	6	6	Drugs and targets
BUSPIRONE	CHEMBL49	Small molecule	Approval	ATC	7	6	6	Drugs and targets
LORAZEPAM	CHEMBL580	Small molecule	Approval	ATC	4	2	2	Drugs and targets
DIAZEPAM	CHEMBL12	Small molecule	Approval	ATC	3	2	2	Drugs and targets
HYDROXYZINE	CHEMBL896	Small molecule	Approval	ATC	3	1	1	Drugs and targets
CLOBAZAM	CHEMBL70418	Small molecule	Approval	ATC	2	1	1	Drugs and targets
ETIFOXINE	CHEMBL2106227	Small molecule	Approval	ATC	2	1	1	Drugs and targets
MEPROBAMATE	CHEMBL979	Small molecule	Approval	ATC	2	0	0	Drugs and targets
ADINAZOLAM	CHEMBL328250	Small molecule	Approval	ATC	1	0	0	Drugs and targets
BENTAZEPAM	CHEMBL1521495	Small molecule	Approval	ATC	1	0	0	Drugs and targets

1 to 10 of 155

See all 155 drugs

Targets184

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA2	GABA-A receptor; anion channel	24	GABA receptor alpha-2 subunit positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA1	GABA-A receptor; anion channel	23	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA3	GABA-A receptor; anion channel	23	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	23	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	23	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	23	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	23	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	23	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	23	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	23	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 184

See all 184 targets

Trials209

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02775864	Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia		81,921	2019-06-07	Schizophrenia, Schizoaffective Disorder	BENZODIAZEPINE	Its record names the disease	ClinicalTrials.gov
NCT03491384	Anxiety, Inflammation, Stress, and Cannabinoids		361	2024-12-09	Anxiety, Anxiety Disorders, Anxiety Generalized, Anxiety Chronic, Inflammation, Inflammatory Response	CANNABIDIOL, DRONABINOL	Its record names the disease	ClinicalTrials.gov
NCT01464697	Progesterone for Perimenopausal Night Sweats	Phase 3	249	2019-12-16	Hot Flushes, Night Sweats	PROGESTERONE	Its record names the disease	ClinicalTrials.gov
NCT01114737	Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients	Phase 3	206	2016-02-01	Phenylketonuria	SAPROPTERIN DIHYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00675909	Improving Sedation of Children Undergoing Procedures in the Emergency Department	Not applicable	180	2012-06-07	Anxiety	MIDAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT00248612	Psychosocial and Medication Treatment for Anxiety in Alcoholism	Phase 2/3	162	2017-08-17	Alcohol-Related Disorders, Anxiety Disorders	VENLAFAXINE HYDROCHLORIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02819141	Self-management of Sedative Therapy by Ventilated Patients	Phase 2/3	161	2025-10-02	Critical Illness, Anxiety, Respiratory Failure	DEXMEDETOMIDINE	Its record names the disease	ClinicalTrials.gov
NCT03069677	Music vs Midazolam During Preop Nerve Block Placement	Phase 3	160	2019-09-10	Anxiety, Peripheral Nerve Block	MIDAZOLAM	Its record names the disease	ClinicalTrials.gov
NCT03649477	Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome	Phase 3	130	2021-11-17	Prader-Willi Syndrome	CARBETOCIN	Its record names the disease	ClinicalTrials.gov
NCT02516332	Exercise and Pharmacotherapy for Anxiety in Cardiac Patients	Not applicable	128	2021-06-11	Anxiety, Cardiovascular Disease	ESCITALOPRAM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 209

See all 209 trials

Comparisons in its trials55

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Oral Micronized Progesterone vs Placebo Comparator: deaths from any cause	0 of 93	0 of 96	189	NCT01464697	Trial comparisons
Oral Micronized Progesterone vs Placebo Comparator: serious adverse events	0 of 93	0 of 96	189	NCT01464697	Trial comparisons
Oral Micronized Progesterone vs Placebo Comparator: Percentage of Women With Perceived Changes in Menstrual Flow	65 of 90	74 of 86	176	NCT01464697	Trial comparisons
Dexmedetomidine vs Control: deaths from any cause	0 of 80	1 of 81	161	NCT02819141	Trial comparisons
Dexmedetomidine vs Control: serious adverse events	12 of 80	5 of 81	161	NCT02819141	Trial comparisons
Music Group vs Midazolam Group: deaths from any cause	0 of 77	0 of 80	157	NCT03069677	Trial comparisons
Music Group vs Midazolam Group: serious adverse events	0 of 77	0 of 80	157	NCT03069677	Trial comparisons
Low Dose Condition (Group) vs High Dose Condition (Group): serious adverse events	0 of 56	0 of 56	112	NCT00465595	Trial comparisons
Intranasal Oxytocin vs Placebo: deaths from any cause	0 of 51	0 of 54	105	NCT03593473	Trial comparisons
Intranasal Oxytocin vs Placebo: serious adverse events	0 of 51	0 of 54	105	NCT03593473	Trial comparisons

1 to 10 of 55

See all 55 comparisons in its trials

Papers from its trials122

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40387497	RESULT	1	PubMed
38337458	RESULT	1	PubMed
38285446	RESULT	1	PubMed
38186562	RESULT	1	PubMed
38132649	RESULT	1	PubMed
37833734	RESULT	1	PubMed
37644380	RESULT	1	PubMed
37404968	RESULT	1	PubMed
37302533	RESULT	1	PubMed
36977985	RESULT	1	PubMed

1 to 10 of 122

See all 122 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011918

GET https://conductscience.org/api/diseases/v1/MONDO_0011918/drugs?page=2

API reference For AI assistants